Lead is found in small quantities in air, soil drinking water and food. Exposure to such amounts of lead does not cause acute lead toxicity, but produces subtle effects, particularly in children. The "safe or acceptable" level of blood lead is up to 10ìg/dl in the general population, and up to 40ìg/dl in the occupationally exposed. The objective of the study was to see if blood levels considered "safe and acceptable" could cause damage to the developing brain producing neurochemical, and neurobehavioral defects.
The study included Albino Wistar rats, which were divided into two-control and the lead-treated groups. The control group was given unleaded water, while the lead-treated group was given 50ppm lead acetate in drinking water. The litters of both these groups were maintained in the same manner for 45 days. On day 45 the experimental animals were weighed, subjected to a passive avoidance test to assess their neurobehavioral faculty, and the blood collected for lead estimation. They were then sacrificed and the brain dissected. The Hippocampus and Striatum were isolated and the neurotransmitter Dopamine and its metabolite DOPAC (Dihydroxyphenyl acetic acid) estimated by HPLC-ECD.
We found that there was a moderate increase in blood lead levels (10.65±3.09ìg/dl as against 4.06±0.07ìg/dl in the controls, p<0.005), while Dopamine was decreased in the Hippocampus (0.86±0.43ng/gm wt. of tissue as against 1.65±0.54ng/gm wt. of tissue in the controls, p<0.05) and Striatum (3.28±2.41ng/gm wt. of tissue as against 15.19±4.46ng/gm wt. of tissue in the controls p<0.005). DOPAC was also found to be decreased. The passive avoidance test showed memory and learning deficits This study showed that exposure to low levels of lead can cause damage to the developing brain and low blood lead levels cannot be considered "safe" or "acceptable" as neurochemical, and neurobehavioral alterations occur even at low blood lead levels. There is an increase in crystallin proteolysis in aged and cataract human lens. The cleaved crystallin fragments are known to interact with intact lens crystallins. The current study was undertaken to identify the crystallin fragments from young, aged and cataract human lenses and study the effect of their interactions with intact lens crystallins.
Crystallin fragments were isolated from the human lenses using 6M urea and filtering through a 10kDa filter. The filtrate was analyzed by mass spectrometry to identify and sequence the peptides. Three crystallin fragments, áB(1-18), âA3/A1(59-74) and ãS(167-178) found in the analyzed lenses were chemically synthesized. The interaction of these peptides with intact á, â and ã-crystallins was studied using sizeexclusion chromatography, dynamic light scattering, HPLC, and by performing chaperone assays.
Peptides derived from áB-crystallin and âA3/A1 caused a concentration dependent increase in the light scattering of âL, and ã-crystallins during thermal aggregation assay while ãS peptide had no effect. Addition of áB and âA3/A1 peptides enhances the aggregation of âL-crystallin by 8 and 10-folds respectively. Interaction with âA3/A1 peptide caused a 5-fold increase in molar mass and a significant increase in polydispersity of áB-crystallin whereas the interaction of áB-with áB peptide resulted in nearly 2-fold increase in molar mass. Additionally, the peptides also decreased the ability of á-crystallin to function as a molecular chaperone. Replacing the hydrophobic residues in peptides decreased their ability to enhance crystallin aggregation. áB(1-18) and âA3/A1(59-74) fragments present in human lenses interact with intact crystallins and induce protein aggregation. Therefore it seems that in vivo generation and interaction of crystallin fragments with crystallins is one of the key events in lens ageing and cataractogenesis. To study changes in manoamine oxidase (MAO) activity, lipid peroxidation levels and lipofuscin accumulation occurring in aging rat brain regions and to see whether these changes are restored to normal levels after exogenous administration of DHEA.
Male Wistar rats of 4 montsh (young). 14 months (adult) and 24 months (old) age groups were used in the study; DHEA was administered intraperitoneally at the dose of 30 mg/kg/day for 30 days. MAO activi8ty was assayed in synaptosomal and supernatant fraction of cerebral hemispheres. Lipid peroxidation was measured in different brain regions by measuring formation of malondialdehyde (MDA) levels. The presence of lipofuscin was observd by fluorescence microscopy in different brain regions.
Present work revealed that aging was associated in significant incrreases in MAO activity, lipid peroxidation and lipofuscin accumulation in brain regions of different age group rats. Present study also showed that exogenous DHEA administration to agin animals significantly decreased MAO activity, lipid peroxidation and lipofuscin accumulation in all three brain regions of agin rats. In the young male rats however DHEA administrations had no effect on the body weight, lipid peroxidation levels, lipofuscin accumulation and monoamine oxidase activity.
In the young male rats no effect of exogenous DHEA can be due to the high levels f endogenous DHEA which does not allowe exogenously administered DHEA to accomodate its binding sites with age related decline in the endogenously DHEA levels after 12-14 months. On the other hand, effects of DHEA at 14 and 24 months old male rats are more profound on the above mentioned parameters. Responsiveness of brain regions of exogenous DHEA was highest in 24 months old male rats. This effect can be attributed to the declining level of endogenous DHEA in aging rats. It can therefore be suggeted that DHEA's beneficial effects seemed to arise from their antioxidative, antiobesity, antilipofuscin and antilipideroxidative actions. The results of such studies will be useful for pharmacological modification of the aging process and development of new drugs.
